Medincell shares resume trading on Euronext Paris

On October 9, 2026, at 2:30 p.m. CEST, Medincell announced the resumption of trading of its shares on Euronext Paris from 2:45 p.m. The suspension had been initiated at the company's request at 9:00 a.m., pending the publication of a press release.

Medincell is a biopharmaceutical company focused on developing long-acting injectable treatments. Among its recent successes is the FDA approval of Olanzapine LAI in October 2026. This treatment for adult schizophrenia will be launched in the United States by Teva, under the name WELTRUZA™, in the fourth quarter of 2026. In May 2026, the EMA accepted an application for marketing authorization for this drug in Europe.